To select a novel small molecule antibiotic for clinical development and advance IT through IND filing and phase 1 clinical studies.

Ended Definitive Contract Awarded Last action

Contract number
75N93020C00018
Awardee
Awarding agency
Obligated
$26,944,787

Award facts

Opportunity
Contract value 80% obligated
  • $26,944,786.61 Current, with exercised options
  • $33,860,136.61 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
San Diego, CA 92101, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00023 $0
Other Administrative Action P00022 $0
Exercise an Option P00021 $2,134,198
Other Administrative Action P00020 $0
Funding Only Action P00019 $670,845
Other Administrative Action P00018 $0
Other Administrative Action P00017 $0
Funding Only Action P00016 $3,823,327
Other Administrative Action P00015 $0
Funding Only Action P00014 $2,818,689
Other Administrative Action P00013 $0
Other Administrative Action P00012 $0
Exercise an Option P00011 $5,121,040
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Exercise an Option P00008 $5,382,870
Funding Only Action P00007 $1,279,569
Other Administrative Action P00006 $0
Funding Only Action P00005 $2,731,729
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $2,982,520
Show all 24

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Revagenix Inc. on July 1, 2020, with a ceiling value of $33.86 million to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies.

The solicitation originated as a Special Notice / Broad Agency Announcement posted January 29, 2019, seeking proposals for development of radiation and nuclear medical countermeasures to mitigate and treat tissue injuries from ionizing radiation exposure. The stated goal was to support research developing safe and effective countermeasures to reduce radiation-associated morbidities and mortalities, with up to $4 million per year in total funding available for one to two awards. Place of performance is San Diego, CA 92101.

The contract is priced on a cost-plus-fixed-fee basis with an ultimate completion date of October 31, 2026. Through FY2024, Revagenix invoiced $6.6 million in government-paid labor across 10.3 FTEs and 21,390 contractor hours, at a derived blended hourly rate of $308.11. The contractor engaged 4 subcontractors performing 77% of contractor hours. Labor intensity has grown year-over-year since FY2021, while the government-paid hourly rate has declined across the period.

Quick answers

Who was awarded contract 75N93020C00018?

75N93020C00018 was awarded to Revagenix Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.

How much is contract 75N93020C00018 worth?

The government has obligated $26,944,787 on 75N93020C00018. Its potential value, with all options, is $33,860,137.

Was contract 75N93020C00018 competed?

The extent of competition for 75N93020C00018 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login